Nephrol Dial Transplant (2002) 17: 1413-1418
© 2002 European Renal Association-European Dialysis and Transplant Association
Optimal dose of losartan for renoprotection in diabetic nephropathy
1 Steno Diabetes Center, Copenhagen, Denmark, 2 Department of Internal Medicine I, University Hospital Dijkzigt, Rotterdam, The Netherlands and 3 Faculty of Health Sciences, University of Aarhus, Denmark
Background. Angiotensin II subtype-1 receptor antagonists represent a valuable new class of drugs in the treatment of diabetic nephropathy. The aim of our study was to evaluate the optimal dose of losartan for renoprotection and blood pressure reduction in diabetic nephropathy.
Methods. Fifty consecutive hypertensive type 1 diabetic patients with diabetic nephropathy received increasing doses of losartan, 50, 100, and 150 mg once daily in three periods each lasting 2 months. At baseline and at the end of each treatment period, albuminuria, 24-h blood pressure (TM2420 A&D), and glomerular filtration rate (GFR) ([51Cr]EDTA plasma clearance) were determined.
Results. Baseline values of albuminuria (geometric mean (95% CI)) and GFR (means±SEM) were 1138 (904–1432) mg/24 h and 91±3 ml/min/1.73 m2, respectively. The blood pressure at baseline was 155/81±3/2 mmHg. All doses of losartan reduced albuminuria and blood pressure. Albuminuria was reduced by 30% (95% CI (15–41)) on losartan 50 mg, 48% (35–57) by losartan 100 mg, and 44% (32–56) by losartan 150 mg (all P values <0.01 vs baseline). Losartan 100 mg daily was significantly more effective than 50 mg daily in reducing albuminuria (P<0.01) without differences between the two high doses. Losartan 50, 100, and 150 mg daily decreased systolic/diastolic blood pressures by 7/4, 12/6, and 10/5 mmHg, respectively (all P<0.05). Losartan 100 mg daily was more effective than 50 mg daily in reducing systolic, diastolic, and mean arterial blood pressure (P=0.05), without differences between the high doses. Treatment with losartan 100 and 150 mg lowered GFR by 4 ml/min/1.73 m2 (P<0.05).
Conclusion. Our study suggests that the optimal dose of losartan is 100 mg daily for renoprotection and blood pressure reduction in type 1 diabetic patients with diabetic nephropathy.
Keywords: albuminuria; angiotensin II; diabetes; hypertension; losartan; nephropathy
Correspondence and offprint requests to: Steen Andersen, Steno Diabetes Center, Niels Steensensvej 2, DK-2820 Gentofte, Denmark. Email: STAN{at}dadlnet.dk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Berl Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2443 - 2447. [Full Text] [PDF]
|
|
|
|
|
|
H.-M. Jin and Y. Pan Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1943 - 1949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. F. Hou, D. Xie, X. Zhang, P. Y. Chen, W. R. Zhang, M. Liang, Z. J. Guo, and J. P. Jiang Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A Randomized Controlled Study of Benazepril and Losartan in Chronic Renal Insufficiency J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1889 - 1898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. De, G. Das, K. Harley, and H. Nair Review: Dual blockade of renin-angiotensin system in diabetic nephropathy: review of literature and local experience The British Journal of Diabetes & Vascular Disease, January 1, 2006; 6(1): 23 - 28. [Abstract] [PDF]
|
|
|
|
 |
|
 P. K. Jacobsen Review: Preventing End-Stage Renal Disease in Diabetic Patients -- Dual Blockade of the Renin-Angiotensin System (Part II) Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2): 55 - 68. [Abstract] [PDF]
|
|
|
|
|
|
L. Vogt, G. Navis, and D. de Zeeuw Individual Titration for Maximal Blockade of the Renin-Angiotensin System in Proteinuric Patients: A Feasible Strategy? J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S53 - S57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. de Zeeuw, G. Remuzzi, H.-H. Parving, W. F. Keane, Z. Zhang, S. Shahinfar, S. Snapinn, M. E. Cooper, W. E. Mitch, and B. M. Brenner Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy Circulation, August 24, 2004; 110(8): 921 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Joss, C. Ferguson, C. Brown, C.J. Deighan, K.R. Paterson, and J.M. Boulton-Jones Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy QJM, April 1, 2004; 97(4): 219 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Laverman, G. Remuzzi, and P. Ruggenenti ACE Inhibition versus Angiotensin Receptor Blockade: Which Is Better for Renal and Cardiovascular Protection? J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S64 - 70. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Rossing, P. Jacobsen, L. Pietraszek, and H.-H. Parving Renoprotective Effects of Adding Angiotensin II Receptor Blocker to Maximal Recommended Doses of ACE Inhibitor in Diabetic Nephropathy: A randomized double-blind crossover trial Diabetes Care, August 1, 2003; 26(8): 2268 - 2274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Jacobsen, S. Andersen, B. R. Jensen, and H.-H. Parving Additive Effect of ACE Inhibition and Angiotensin II Receptor Blockade in Type I Diabetic Patients with Diabetic Nephropathy J. Am. Soc. Nephrol., April 1, 2003; 14(4): 992 - 999. [Abstract] [Full Text] [PDF]
|
|